Eli Lilly expands obesity drug sales through Hims & Hers platform

Eli Lilly expands obesity drug sales through Hims & Hers platform
Lilly expands drug reach

Eli Lilly is broadening its direct-to-consumer obesity drug distribution by allowing Hims & Hers Health to sell Zepbound and Foundayo directly on its telehealth platform. The agreement removes a previous step that required patients to leave the site for LillyDirect and comes as competition intensifies in the fast-growing weight-loss drug market.

Highlights

  • Eli Lilly signed a distribution deal allowing Hims & Hers to sell Foundayo and Zepbound directly on its platform, bypassing LillyDirect's cash-pay site and matching monthly prices at $149 and $299, respectively.
  • Hims & Hers shares jumped over 7% premarket after the announcement, with the agreement prohibiting sale of compounded or knockoff versions of Lilly's obesity drugs.
  • Lilly, the obesity drug market leader with Zepbound, raised its 2024 full-year revenue forecast by $5 billion amid strong demand, while about 40%–45% of Zepbound sales come from self-pay channels.

Distribution deal broadens patient access

As reported by Reuters, the new agreement lets Hims & Hers offer Lilly's obesity treatments directly on its own platform, instead of sending patients to Lilly's separate cash-pay site. Hims & Hers shares rose more than 7% in premarket trading after the announcement.

Ilya Yuffa, president of Lilly USA, said the previous process was not fully straightforward for users on the Hims & Hers platform. He said friction in the buying process raises the likelihood that consumers abandon treatment before completing a purchase.

Under the deal, Hims & Hers has agreed not to sell compounded versions or knockoffs of Lilly's obesity medicines, Yuffa said. Self-pay pricing starts at $149 a month for the oral drug Foundayo and $299 a month for injectable GLP-1 treatment Zepbound, matching the prices offered through LillyDirect.

Competitive pressure builds in obesity market

Novo Nordisk has been selling Wegovy and Ozempic through Hims & Hers since March, putting Lilly's latest move on similar footing with its Danish rival. Novo had previously sued the telehealth company for offering compounded versions of its drugs, and its products on the platform start at $149 a month for the Wegovy pill and $199 a month for the Wegovy injector pen.

Lilly remains the leader in the obesity drug market with injectable Zepbound, while Novo has sold millions more obesity pills in the U.S. Lilly launched oral Foundayo in April, around three months after Novo's Wegovy pill reached the market.

About 40% to 45% of Zepbound sales come through self-pay channels, according to Lilly. Analysts have said Hims & Hers may benefit next year if employers reduce coverage for weight-loss drugs to control costs, while Lilly last week raised its full-year revenue forecast by $5 billion on strong demand for its injectable treatments.

Our earlier article on the Nasdaq-100 highlighted the launch of JQQQ, a blockchain-native fund designed to give investors digital access to the index. We also noted that, despite this new access route, the NDX remained under near-term selling pressure with key resistance and downside levels in focus.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.